European Launch Power Accord Healthcare maintains a strong European launch capability and a broad global footprint, positioning it well to partner on co-launches and market access initiatives across Europe and nearby regions for affordable medicines.

Biosimilar Momentum The company has launched denosumab biosimilars after patent expiry, backed by regulatory endorsement, signaling a mature biosimilars program and opportunities for licensing, contract manufacturing, and wide distribution in Europe and the Middle East.

Capacity Growth Recent manufacturing expansions and capacity upgrades funded by strategic investment demonstrate the ability to scale supply for new products, creating potential for contract or toll manufacturing partnerships.

Public Sector Focus A clear emphasis on delivering affordable medicines to national health systems aligns with government tenders and multi-country supply agreements, offering opportunities for exclusive distribution deals and value-based partnerships with health authorities.

Strategic Partnerships Active international partnerships and regional subsidiaries indicate a growth-oriented strategy open to licensing, co-development, and distribution alliances across Europe, the Middle East, and other markets.